Lyme Disease-Pipeline Insight, 2021 | Analytical Research Cognizance

Lyme Disease-Pipeline Insight, 2021

Published by ARCDI001
Report ID 1667937
Published date Mar 30, 2021
Category Pharmaceuticals and Healthcare
Total Pages 60
Choose license type Buy Now
Request a Sample Enquiry Before Buying Check Discount

DelveInsight’s, “Lyme Disease - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Lyme Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Global coverage
Lyme Disease Understanding
Lyme Disease: Overview
Lyme disease is the most common vector-borne disease in the United States. Lyme disease is caused by the bacterium Borrelia burgdorferi and rarely, Borrelia mayonii. It is transmitted to humans through the bite of infected blacklegged ticks. Typical symptoms include fever, headache, fatigue, and a characteristic skin rash called erythema migrans. If left untreated, infection can spread to joints, the heart, and the nervous system. Lyme disease is diagnosed based on symptoms, physical findings (e.g., rash), and the possibility of exposure to infected ticks. Laboratory testing is helpful if used correctly and performed with validated methods. Most cases of Lyme disease can be treated successfully with a few weeks of antibiotics. Steps to prevent Lyme disease include using insect repellent, removing ticks promptly, applying pesticides, and reducing tick habitat. The ticks that transmit Lyme disease can occasionally transmit other tickborne diseases as well.
"Lyme Disease - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Lyme Disease pipeline landscape is provided which includes the disease overview and Lyme Disease treatment guidelines. The assessment part of the report embraces, in depth Lyme Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Lyme Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Lyme Disease R&D. The therapies under development are focused on novel approaches to treat/improve Lyme Disease.
Lyme disease Emerging Drugs Chapters
This segment of the Lyme Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Lyme Disease Emerging Drugs
VLA 15: Valneva
VLA15 is a multivalent, protein subunit vaccine that targets the outer surface protein A (OspA) of Borrelia, an established mechanism of action for Lyme disease vaccine. OspA is one of the most dominant surface proteins expressed by the bacteria when present in a tick. Valneva and Pfizer announced a collaboration to develop and commercialize VLA15 in April 2020. The VLA15 program was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) in July 2017. VLA15 is in Phase 2 clinical development5: Valneva announced positive initial results for its two Phase 2 studies, VLA15-2016 and VLA15-2027, in July and October 2020 respectively. Valneva and Pfizer plan to accelerate pediatric development of VLA15, with the initiation of study VLA15-221 in the first quarter of 2021, subject to regulatory approval.
CT 38: Cortene
CT38 is a potent, short-lived, peptide agonist selective for CRF2. It is comprised entirely of naturally-occurring amino acids. It is currently in Phase I for Lyme disease and is being developed by Cortene.
Further product details are provided in the report……..

Lyme Disease: Therapeutic Assessment
This segment of the report provides insights about the different Lyme Disease drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Lyme Disease
There are approx. 5+ key companies which are developing the therapies for Lyme Disease. The companies which have their Lyme Disease drug candidates in the most advanced stage, i.e. Phase II include, Valneva.
Phases
DelveInsight’s report covers around 5+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Lyme Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Parenteral
Intravitreal
Subretinal
Topical

Molecule Type
Products have been categorized under various Molecule types such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Lyme Disease: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Lyme Disease therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Lyme Disease drugs.

Lyme Disease Report Insights
Lyme Disease Pipeline Analysis
Therapeutic Assessment
Unmet Needs
Impact of Drugs
Lyme Disease Report Assessment
Pipeline Product Profiles
Therapeutic Assessment
Pipeline Assessment
Inactive drugs assessment
Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
How many companies are developing Lyme Disease drugs?
How many Lyme Disease drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Lyme Disease?
What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Lyme Disease therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Lyme Disease and their status?
What are the key designations that have been granted to the emerging drugs?

Key Players
Valneva
Cortene
Tarsus Pharmaceuticals
Flightpath Biosciences

Key Products
VLA 15
CT 38
TP 05
FP-101

Introduction
Executive Summary
Lyme Disease: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Lyme Disease – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Lyme Disease companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Lyme Disease Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
VLA 15: Valneva
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
CT 38: Cortene
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
FP-101: Flightpath Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Lyme Disease Key Companies
Lyme Disease Key Products
Lyme Disease- Unmet Needs
Lyme Disease- Market Drivers and Barriers
Lyme Disease- Future Perspectives and Conclusion
Lyme Disease Analyst Views
Lyme Disease Key Companies
Appendix

Table 1 Total Products for Lyme Disease
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Figure 1 Total Products for Lyme Disease
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products